Skip to main content
Premium Trial:

Request an Annual Quote

Ventana to Develop CDx for Merck KGaA

NEW YORK (GenomeWeb) – Ventana Medical Systems today said that it will collaborate with Merck KGaA on a companion diagnostic test for an undisclosed therapeutic target.

According to the firms, Ventana will develop and validate the CDx test for future clinical studies. Further details of the collaboration were not disclosed.

Tucson, Ariz.-based Ventana, which is part of the Roche Group, has several collaborations with biopharmaceutical firms to develop companion diagnostic products. Among its other partners are Bayer, Pfizer, Boehringer Ingelheim, and Takeda's Millennium unit. Last week it announced a deal to develop a companion diagnostic for a MedImmune drug in development for non-small cell lung cancer.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.